Bigul

Jubilant Pharmova Ltd - 530019 - Jubilant Pharmova - Q3 FY 2023 Results

In terms of Regulation 33 read with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that Board of Directors of Jubilant Pharmova Ltd at its meeting held today i.e. Friday, February 03, 2023 considered and approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended December 31, 2022. Copy of the unaudited financials results for the quarter ended December 31, 2022 alongwith Limited Review Reports issued by the Statutory Auditors on the Unaudited Financial Results (Standalone and Consolidated) for the said period and Press Release/Presentation on aforesaid financials is enclosed herewith. The Board Meeting commenced at 11:15 a.m. and concluded at 12.50 p.m. All the above mentioned documents will be simultaneously posted on the Company''s website at www.jubilantpharmova.com. You are requested to take note of the same.
03-02-2023
Bigul

Jubilant Pharmova Ltd - 530019 - Schedule Of Investor Conference Call For Jubilant Pharmova Limited - Unaudited Financial Results For The Quarter Ended December 31, 2022

We refer to our letter dated January 27, 2023 regarding schedule of Investor Conference Call, we wish to inform you that the Conference Call scheduled on February 3, 2023 at 5.00 pm has been preponed to 4.00 pm on February 3, 2023. Revised details of the Conference Call are attached. This is for information and record.
01-02-2023
Bigul

Jubilant Pharmova Ltd - 530019 - USFDA Approval

We enclose communication pertaining to USFDA Approval
31-01-2023
Bigul

Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Schedule of Investor Conference Call - Unaudited Financial Results for the quarter and nine months ended December 31, 2022
27-01-2023
Bigul

Jubilant Pharmova Ltd - 530019 - Board Meeting Intimation for Consideration Of, Inter-Alia, Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2022

Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2023 ,inter alia, to consider and approve Consideration of, inter-alia, Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2022
25-01-2023
Bigul

Jubilant Pharmova Ltd - 530019 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018
10-01-2023
Bigul

Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Credit Rating

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that India Ratings and Research Private Limited has assigned Long-term issuer rating of 'IND AA+' Rating for Jubilant Pharmova Limited.
27-12-2022
Bigul

Jubilant Pharmova Ltd - 530019 - Closure of Trading Window

Closure of trading window
23-12-2022
Bigul

Jubilant Pharmova Ltd - 530019 - Completion Of Inspection By USFDA

Completion of inspection by USFDA
14-12-2022
Next Page
Close

Let's Open Free Demat Account